What is Oruka Therapeutics, Inc.'s free cash flow yield?

Oruka Therapeutics, Inc. (ORKA) reported free cash flow yield of -3.8% in Q1 2026.

What does free cash flow yield mean?

Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.

Oruka Therapeutics, Inc. ORKA Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers SquibbBMY

9.6%-0.9pp

Eli LillyLLY

1.4%+0.9pp

Johnson & JohnsonJNJ

3%-2.1pp

AmgenAMGN

4.5%-2.0pp

AbbVieABBV

5.2%+1.0pp

Kymera TherapeuticsKYMR

-3.6%-1.5pp

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$4.36B+533%

Enterprise value$4.32B+690%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

free cash flow/market cap=-3.8%

Based on trailing twelve months.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s free cash flow yield?: Oruka Therapeutics, Inc. (ORKA) reported free cash flow yield of -3.8% in Q1 2026.
What does free cash flow yield mean?: Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.